A meta-analysis of serological response associated with yellow fever vaccination

American Journal of Tropical Medicine and Hygiene

Volumn 95, Issue 6, 2016, Pages 1435-1439

  Jean, Kévin ^a   Donnelly, Christl A ^a   Ferguson, Neil M ^a   Garske, Tini ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

YELLOW FEVER VACCINE; VIRUS ANTIBODY;

ARTICLE; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; META ANALYSIS; SEROCONVERSION; SEROLOGY; SYSTEMATIC REVIEW (TOPIC); VACCINATION; YELLOW FEVER; BLOOD; IMMUNOLOGY;

ANTIBODIES, VIRAL; HUMANS; SEROLOGIC TESTS; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 85005981013     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.16-0401     Document Type: Article

References (21)

1. Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE, Perea W, Ferguson NM, Committee Yellow Fever Expert, 2014. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med 11: e1001638.
2. World Health Organization-Incident Management Team Angola, 2016. Situation Report: Yellow Fever Outbreak in Angola, 4 July 2016. Available at: http://www.afro.who.int/en/yellowfever/sitreps/item/8782-situation-report-yellow-fever-outbreakin-angola-4-july-2016.html. Accessed July 19, 2016.
3. Frierson JG, 2010. The yellow fever vaccine: a history. Yale J Biol Med 83: 77-85.
4. Gotuzzo E, Yactayo S, Córdova E, 2013. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 89: 434-444.
5. World Health Organization, 2013. Vaccines and vaccination against yellow fever. WHO position paper: June 2013. Wkly Epidemiol Rec 88: 269-283.
6. Groot H, Gast-Galvis A, 1965. Observations on the 17 D virus vaccine against yellow fever, applied by cutaneous scarification [in Spanish]. Rev Invest (Guadalajara) 5: 5-25.
7. Guerra HL, Sardinha TM, da Rosa AP, Lima e Costa MF, 1997. Effectiveness of the yellow fever vaccine 17D: an epidemiologic evaluation in health services [in Portuguese]. Rev Panam Salud Publica 2: 115-120.
8. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J, 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159-167.
9. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P, 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533-541.
10. Vázquez S, Valdés O, Pupo M, Delgado I, Álvarez M, Pelegrino JL, Guzmán MG, 2003. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. J Virol Methods 110: 179-184.
11. Tavares-Neto J, Freitas-Carvalho J, Nunes MRT, Rocha G, Rodrigues SG, Damasceno E, Darub R, Viana S, Vasconcelos PF, 2004. Serologic survey for yellow fever and other arboviruses among inhabitants of Rio Branco, Brazil, before and three months after receiving the yellow fever 17D vaccine [in Portuguese]. Rev Soc Bras Med Trop 37: 1-6.
12. Camacho LA, Freire Mda S, Leal Mda L, Aguiar SG, Nascimento JP, Iguchi T, Lozana Jde A, Farias RH, Collaborative Group for the Study of Yellow Fever Vaccines, 2004. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saúde Pública 38: 671-678.
13. Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, Pastor-Cauna G, Echevarria C, Laguna-Torres VA, Samame BK, Baldeon ME, Burans JP, Olson JG, Bedford P, Kitchener S, Monath TP, 2005. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 72: 189-197.
14. Pfister M, Kürsteiner O, Hilfiker H, Favre D, Durrer P, Ennaji A, L'Age-Stehr J, Kaufhold A, Herzog C, 2005. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 72: 339-346.
15. Suzano CE, Amaral E, Sato HK, Papaiordanou PM, Campinas Group on Yellow Fever Immunization during Pregnancy, 2006. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24: 1421-1426.
16. de Melo AB, da Silva Mda PC, Magalhães MC, Gil LHG, de Carvalho EMF, Braga-Neto UM, Bertani GR, Marques ET Jr, Cordeiro MT, 2011. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 85: 739-747.
17. Mason RA, Tauraso NM, Spertzel RO, Ginn RK, 1973. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25: 539-544.
18. Viechtbauer W, 2010. Conducting meta-analyses in R with the metafor package. J Stat Softw 36 1-48.
19. Egger M, Davey Smith G, Schneider M, Minder C, 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
20. Collaborative Group for Studies of Yellow Fever Vaccine, 2015. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz 110: 771-780.
21. Monath TP, Woodall JP, Gubler DJ, Yuill TM, Mackenzie JS, Martins RM, Reiter P, Heymann DL, 2016. Yellow fever vaccine supply: a possible solution. Lancet 387: 1599-1600.